Loading...
01/11 03:45
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: a decline in revenue and increased R&D expenses and net loss. Despite the clinical pipeline progress, the market may react negatively to the financial results. The Q&A section highlights uncertainties in dosing strategies and management's reluctance to disclose specific milestone details, which could further erode investor confidence. The positive aspects, such as cash runway and pipeline advancements, are overshadowed by financial underperformance and lack of clarity in strategic execution.
Revenue $8.7 million for Q2 2025, a decrease from $19.7 million in Q2 2024. The year-over-year decrease was due to the timing of revenue recognized under the collaboration agreement with GSK.
Research and Development Expenses $43.5 million for Q2 2025, an increase from $40.4 million in Q2 2024. The increase was primarily driven by spending in the INHBE program, RNA editing programs, and compensation-related expenses, including share-based compensation.
General and Administrative Expenses $18 million for Q2 2025, an increase from $14.3 million in Q2 2024. The increase was primarily related to share-based compensation and other external expenses.
Net Loss $50.5 million for Q2 2025, an increase from $32.9 million in Q2 2024. The increase was driven by higher R&D and G&A expenses.
Cash and Cash Equivalents $208.5 million as of the end of Q2 2025, a decrease from $302.1 million as of December 31, 2024. The decrease reflects operational spending.
WVE-006 for AATD: Designed to address the root cause of alpha-1 antitrypsin deficiency (AATD) with a subcutaneous therapeutic. Demonstrated impressive durability and safety in trials, with data showing potential for monthly or less frequent dosing.
WVE-007 for obesity: Advanced INLIGHT clinical study with favorable safety and tolerability. Expanded second cohort dosing and initiated third cohort. Data expected to show healthy weight loss with infrequent dosing.
WVE-N531 for DMD: Demonstrated significant improvement in muscle health and function in boys with exon 53 amenable Duchenne muscular dystrophy (DMD). Plans to submit NDA in 2026 for accelerated approval.
WVE-003 for HD: Preparing for a Phase II/III study for Huntington's disease (HD) with allele-selective approach. Demonstrated potent mutant huntingtin reductions and correlation with slowing caudate atrophy.
RNA editing leadership: Continued leadership in RNA editing with advancements in clinical programs for AATD, obesity, and DMD.
Strategic partnerships: Actively engaged in discussions with prospective partners for HD program.
Financial performance: Revenue decreased to $8.7M from $19.7M YoY due to timing of collaboration revenue. Net loss increased to $50.5M from $32.9M YoY. Cash reserves at $208.5M, sufficient to fund operations into 2027.
R&D and G&A expenses: R&D expenses increased to $43.5M due to spending on INHBE and RNA editing programs. G&A expenses rose to $18M due to share-based compensation and external expenses.
Pipeline expansion: Advancing wholly owned discovery pipeline with new RNA editing and siRNA programs targeting hepatic and extrahepatic diseases. Clinical development of new programs expected in 2026.
Regulatory engagement: Positive FDA interactions for DMD and HD programs, aligning on next steps for accelerated approval and trial designs.
Regulatory Risks: The company faces potential regulatory hurdles as it prepares for key data readouts and regulatory filings for its pipeline programs, including WVE-006 and WVE-003. The success of these filings is critical for advancing their clinical programs.
Financial Risks: The company reported a significant net loss of $50.5 million for Q2 2025, compared to $32.9 million in the prior year. This financial strain could impact its ability to sustain operations and fund ongoing research and development.
Pipeline Development Risks: There is uncertainty in the clinical outcomes of key programs such as WVE-006 for AATD and WVE-007 for obesity. The success of these programs is crucial for the company's strategic objectives.
Market Competition: The company faces competitive pressures, particularly in the obesity treatment market, where GLP-1 agonists are the current standard of care. Differentiating its product, WVE-007, will be essential to gain market share.
Supply Chain and Operational Risks: The company’s ability to rapidly recruit, enroll, and dose participants in clinical trials is critical. Any disruptions in these processes could delay key data readouts and impact strategic timelines.
Economic and Funding Risks: The company’s cash and cash equivalents decreased significantly from $302.1 million at the end of 2024 to $208.5 million in Q2 2025. While the company expects to fund operations into 2027, this is contingent on achieving milestones and securing additional funding.
WVE-006 for AATD: Data from the complete 200-milligram single and multi-dose cohorts will be delivered in Q3 2025, and single-dose data from the 400-milligram cohort will be available in fall 2025. Multi-dose data will inform the therapeutic potential and dosing intervals for WVE-006.
WVE-007 for Obesity: Data from the expanded 240-milligram second dose cohort and the 75-milligram Cohort 1 will be delivered in Q4 2025. Data from the 400-milligram third dose cohort will be available in Q1 2026. The program aims to demonstrate healthy weight loss with infrequent dosing.
WVE-N531 for DMD: An NDA submission for accelerated approval is planned for 2026, with a monthly dosing regimen. A global confirmatory trial design is also planned.
WVE-003 for HD: A global Phase II/III study is planned for submission in the second half of 2025, using caudate volume as a primary endpoint. The study aims to address the full spectrum of HD with an allele-selective approach.
Pipeline Expansion: New clinical programs are expected to be initiated in 2026, including RNA editing and siRNA programs targeting hepatic and extrahepatic tissues.
dividend program: No mention of a dividend program was made during the conference call.
shares buyback program: No mention of a shares buyback program was made during the conference call.
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
The earnings call reveals several concerns: a decline in revenue and increased R&D expenses and net loss. Despite the clinical pipeline progress, the market may react negatively to the financial results. The Q&A section highlights uncertainties in dosing strategies and management's reluctance to disclose specific milestone details, which could further erode investor confidence. The positive aspects, such as cash runway and pipeline advancements, are overshadowed by financial underperformance and lack of clarity in strategic execution.
The earnings call summary shows challenges: declining revenue, increased expenses, and a significant net loss, indicating financial strain. The absence of a shareholder return plan is concerning. The Q&A section reveals uncertainties, particularly regarding data disclosure timelines and regulatory approval pathways. Competitive pressures from GLP-1s in obesity treatment and supply chain challenges further exacerbate the negative outlook. While there are some positive aspects, such as cash runway until 2027, the overall sentiment remains negative due to financial strain and uncertainties, likely leading to a stock price decline of -2% to -8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
